Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: vladz who wrote (420)	3/10/2005 11:03:39 AM
From: vladz	Respond to of 508

InterMune Announces Webcast of Corporate Presentation at the SG Cowen & Co. 25th Annual Health Care Conference Wednesday March 9, 4:11 pm ET BRISBANE, Calif., March 9 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN - News) announced today that the Company will present at the 25th Annual SG Cowen & Co. Health Care Conference in Boston, MA. The presentation will begin at 9:40 a.m. (EST), Wednesday, March 16th, 2005. To access the live audio webcast, log on to the investor relations page of the Company's website at www.intermune.com. We recommend logging on 15 minutes early in order to register or download any necessary software. ADVERTISEMENT About InterMune InterMune is a biopharmaceutical company focused on developing and commercializing innovative therapies in hepatology and pulmonology. The Company has a broad and deep late-stage product portfolio addressing hepatitis C virus (HCV) infections, particularly nonresponders, or those patients who do not respond to first-line therapy, and idiopathic pulmonary fibrosis (IPF). Leading the hepatology portfolio is the DIRECT Trial, a Phase III study of daily Infergen plus ribavirin, and a Phase IIb trial of daily Infergen plus Actimmune with and without ribavirin for the treatment of HCV nonresponders. In addition, InterMune has an early stage small molecule program targeted at the HCV protease. The pulmonology portfolio includes pirfenidone and Actimmune. Pirfenidone is being developed for the treatment of IPF and for the treatment of Hermansky-Pudlak Syndrome. Actimmune is being investigated in the INSPIRE Trial, a Phase III study in patients with IPF. For additional information about InterMune and its development pipeline, please visit www.intermune.com.